Clinical Trial Update: KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases [Phase 3]

View source ↗

Summary

Khondrion's KHENERFIN study is a Phase 3 trial evaluating Sonlicromanol for mitochondrial diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Maternally Inherited Diabetes and Deafness
• Mitochondrial Diseases
• Mitochondrial Dna Trnaleu 3243a Mutation
• Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like Episodes

Drugs mentioned

• KHENERFIN (Sonlicromanol)

Snippet

Sponsor: Khondrion BV | Conditions: Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD) | Phase 3 | Status: RECRUITING